Hangzhou AGS MedTech Co. Ltd. A (688581) — Capital Reinvestment Ratio
Latest as of December 2025:
0.42x
Hangzhou AGS MedTech Co. Ltd. A (688581) has a Capital Reinvestment Ratio of 0.42x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥151.20 Million) in capital expenditures (CN¥63.47 Million). See cash generation quality of Hangzhou AGS MedTech Co. Ltd. A to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.42x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥151.20 Million
CNY
Capital Expenditures
CN¥63.47 Million
CNY
Data as of
Dec 2025
Most recent filing
Hangzhou AGS MedTech Co. Ltd. A Capital Reinvestment Ratio (2021–2025)
This chart tracks Hangzhou AGS MedTech Co. Ltd. A's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
Year-by-year Capital Reinvestment Ratio for Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025. For live market cap and broader valuation context, see 688581 market cap.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.42x | CN¥151.20 Million | CN¥63.47 Million | ▲ +167.2% |
| 2024 | 0.16x | CN¥315.80 Million | CN¥49.60 Million | ▼ -32.6% |
| 2023 | 0.23x | CN¥221.45 Million | CN¥51.57 Million | ▼ -39.4% |
| 2022 | 0.38x | CN¥156.38 Million | CN¥60.12 Million | ▲ +190.3% |
| 2021 | 0.13x | CN¥118.25 Million | CN¥15.66 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow